
# Formulation Recommendation



## **Advantol 300 Antacid Soft Chew**

| Composition                           | % (By Weight) | mg / Tablet |
|---------------------------------------|---------------|-------------|
| 🔵 1 Calmag                            | 44.90         | 217.39      |
| e 2 Advantol <sup>®</sup> 300         | 40.60         | 828.41      |
| 3 Merisorb <sup>®</sup> SD 250 Pharma | 10.00         | 60.00       |
| 4 Lubripharm <sup>®</sup> SSF         | 2.00          | 30.00       |
| 9 5 Orange Flavor                     | 1.89          | 24.00       |
| • 6 Sucralose                         | 0.50          | 15.00       |
| <b>7</b> FD&C Yellow #5               | 0.08          | 0.90        |
| • 8 FD&C Red #40                      | 0.03          | 0.30        |
|                                       | 1176.00       |             |



### **General Tablet Characteristics**

| Advantol<br>300 Antacid<br>Soft Chew | Tablet<br>Thickness<br>(mm) | Tablet<br>Hardness<br>(kP) | Tablet<br>Disintegration<br>(s) | Friability<br>(%) |
|--------------------------------------|-----------------------------|----------------------------|---------------------------------|-------------------|
| Average                              | 4.28                        | 11.00                      | 45.00                           | 0.21              |

# Method

- Weigh the components individually and screen all non-lubricant and non-colorants using a #20-mesh sieve. Seperately, take the Lubripharm, FD&C Red and FD&C Yellow and co-screen using a #20-mesh sieve.
- Mix all ingredients, with the exception of the Lubripharm, FD&C Red and FD&C Yellow co-screen, in an 8-qt V-blender at 25rpm for 15 minutes.
- 3. Add the Lubripharm, FD&C Red and FD&C Yellow co-screen to the first mixture and blend for an additional 5 minutes.
- 4. Compress the formulation to 1176mg tablets on a rotary tablet press outfitted with 0.625" FFBE type "D" punches, operated at 25rpm with a pre-compression force of 1kN to a tablet hardness of 11kP.

www.spipharma.com

#### Your Partner for Formulating Success

| Americas<br>SPI Pharma, Inc.<br>Rockwood Office Park<br>503 Carr Rd., Suite 210<br>Wilmington, DE 19809 | Europe/Middle East/ Africa<br>SPI Pharma SAS<br>Chemin du Vallon du Maire<br>13240 Septemes-Les Vallons<br>France | Asia/Pacific<br>SPI Pharma, Inc – India Branch<br>21 B, Veerasandra Industrial Area<br>Hosur Road, Bangalore – 560100<br>Karnataka, India |                                      | SPI Pharma <sup>-</sup> |
|---|---|---|--------------------------------------|-------------------------|
| T 302 576 8600<br>800 789 9755 Ext. 8600<br>F 302 576 8567  | T 33 4 9196 3600<br>F 33 4 9196 3633  | T 91 80 3027 0005<br>F 91 80 3027 0050  | T 61 2 9475 2200<br>F 61 2 9475 2211 |                         |

All trademarks are the property of SPI Pharma. Copyright SPI Pharma 2013. The information contained in this document is proprietary to SPI Pharma and may not be used or disseminated inappropriately. The information and recommendations contained herein are to the best of SPI Pharma, Inc.'s knowledge reliable and accurate. Any recommendations are made without warranty, either implied or expressed, due to the variations in equipment, conditions, and methods which may be used in commercially processing the products. No warranties of any kind are made, express or implied, including those of merchantability and fitness for particular purpose, other than the products conform to current standard specifications. SPI Pharma, Inc. makes no warranty that the use of the products or formulations provided by SPI Pharma, Inc. will not infringe any trademark, trade name, copyright, patent or other rights held by any third party when used in customer's application. SPI Pharma, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damage.